



Rec'd PCT/PTO 16 JUL 2004
PCT/GB 2003 / 001264



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 04 JUN 2003

WIPO

PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)


Signed

Andrew Gensay

Dated

14 April 2003

BEST AVAILABLE COPY



1/77

16APR02 E711246-1 D02834
P01/7700 0.00-0208642.9

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference 15651 MdH

2. Patent application number 0208642.9 16 APR 2002
(The Patent Office will fill in this part)

3. Full name, address and postcode of the or of each applicant (underline all surnames)
Accentus plc
329 Harwell
Didcot, Oxfordshire, OX11 0QJ
United Kingdom

Patents ADP number (if you know it)

8125 833001

If the applicant is a corporate body, give the country/state of its incorporation

England and Wales

4. Title of the invention
Metal implants

5. Name of your agent (if you have one)
"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)
Peter Turquand Mansfield
Accentus plc
Patents Department, 329 Harwell
Didcot, Oxfordshire, OX11 0QJ

Patents ADP number (if you know it)

8143497001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of filing (day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application	Date of filing (day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

See note (d))

Yes

BEST AVAILABLE COPY

Metal Implants

This invention relates to metal implants for use in surgical procedures, and in particular to the
5 introduction of a biocidal material into such implants to suppress or control infection.

Various surgical procedures require the use of implants. For example cancerous bone may be removed, in
10 prosthetic surgery, to be replaced by a metal implant. Such an implant may for example be of titanium alloy, which is very strong and relatively light. To ensure a hard-wearing surface the provision of a titanium nitride coating has been suggested. There is furthermore a risk
15 of introducing infection when implanting such metal implants, and it has been suggested that metallic silver might be electroplated onto metal implants, the silver being a biocidal material that can control infection without causing toxic effects to the patient. However
20 such coatings, whether of titanium nitride or silver, may be undercut due to corrosion from body fluids, so that the coating may detach from the implant, which may can increase wear and cause tissue damage.

25 According to the present invention there is provided a metal implant for use in a surgical procedure, the implant having a surface layer that is integral with the metal substrate, and which incorporates a biocidal material.

30 Such an integral surface layer may be generated by growing the layer from the metal itself, for example by an anodising process; or alternatively by depositing the layer for example by electroplating, followed by
35 diffusion bonding so that the layer becomes integral with the metal of the implant. Anodising forms an adherent

oxide layer, although if it is carried out in phosphoric acid then a phosphate may be formed. Such an adherent phosphate layer may also be modified to form a hydroxyapatite layer, which can stimulate bone growth.

5

The biocidal material should preferably be effective for at least 6 weeks, preferably for up to 6 months after surgery, and the release rate should be low to avoid toxic effects on body cells. Furthermore the total
10 quantity of biocidal material is preferably also limited to minimize any toxic effects.

It is also desirable if the surface is highly polished before production of the surface layer. This
15 may for example be achieved by electropolishing.

In principle, a range of different materials may be used for the biocidal material. In particular, if the layer is a metal layer deposited by electroplating then
20 it clearly must be stable to corrosion. Gold, platinum, iridium and palladium would be potentially suitable, although expensive; silver is preferable as it is not particularly soluble in body fluids due to the presence of chloride ions and the low solubility of silver
25 chloride. If the surface layer contains a biocidal metal in ionic form, then a wider range of metals would be possible. In addition to the elements already mentioned, copper, tin, antimony, lead, bismuth and zinc might be used as ions combined into an insoluble matrix for
30 example of metal oxide or metal phosphate. The rate of release would be controlled, in this case, primarily by the strength of the absorption of the metal ions in the matrix.

35 The metals that may be used to make such prosthetic implants are typically a form of stainless steel, a

titanium alloy, or a cobalt/chromium alloy, although zirconium could also be used. The standard alloys for this purpose are titanium 90 percent with 6 percent aluminium and 4 percent vanadium (British standard 7252),
5 or chromium 26.5-30 percent, molybdenum 4.5-7 percent, and the remainder cobalt (British standard 7252 part 4).

Preferably the implant is initially polished to
10 provide a very smooth surface. Both stainless steel (chromium/iron/nickel) and cobalt/chromium alloy can be electro-polished using as electrolyte a mixture of phosphoric acid and glycerine, or a mixture of phosphoric acid and sulphuric acid. Titanium alloy can be electro-
15 polished using acetic acid, or a mixture of nitric and hydrofluoric acids. Alternatively the implants might be subjected to a combination of anodic passivation with mechanical polishing, which may be referred to as electrolinishing, this process removing the oxide that
20 protects surface roughness, the surface at that point then being electrochemically re-passivated, so producing a mirror-smooth finish. Various electrolytes are suitable for this purpose, including nitric acid mixed with sulphuric acid, sodium hydroxide, sodium phosphate,
25 or sodium hydroxide mixed with sodium nitrate.

After polishing the surface of the metal, either silver deposition or surface conversion can take place. Considering surface conversion first, a layer of metal
30 oxide or phosphate may be formed by anodising in a suitable electrolyte, so that the oxide or phosphate layer builds out from the surface of the metal. Biocidal metal ions can then be absorbed from an aqueous salt solution into the oxide or phosphate matrix, for example
35 the ions Ag^+ or Cu^{++} . Cations of palladium, platinum or even ruthenium could be absorbed in a similar way. If

desired, deposited silver, platinum or palladium ions could then be converted to metal, or deposited ruthenium ions converted to insoluble RuO_2 , within the oxide or phosphate surface coating, this reaction being performed
5 chemically or electrochemically or by light.

Considering now silver deposition, the coating should be thin to prevent toxic effects. A high degree of adherence to the underlying metal can be ensured by
10 first removing the surface oxide layer by anodic etching, followed by a brief reversal of polarity in the presence of appropriate ions, so as to cover the surface with a thin coating of silver. This may be repeated to ensure there are no pin-holes. The plating electrolyte may
15 include hydrofluoric acid, or may be an alkaline cyanide electroplating electrolyte. After deposition, the silver coating should be diffusion bonded so as to form an inter-metallic layer, by heating the implant to an elevated temperature. Typically it should be heated to
20 above 1000°C , in an inert atmosphere for example of argon. This substantially eliminates the risk of coating delamination.

In place of silver, other metals such as platinum or
25 palladium may be electro-deposited and then thermally treated in a similar fashion so as to form an inter-metallic layer.

The invention will now be further and more
30 particularly described, by way of example only.

A hip implant is made of titanium alloy (Ti/Al/V). The implant is cleaned ultrasonically using first acetone as the liquid phase, and then a 1 M aqueous solution of
35 sodium hydroxide, and is then rinsed in de-ionised water. The cleaned implant is then immersed in a stirred 12

weight percent solution of phosphoric acid, and is anodized for 2 hours at a maximum voltage of 10 V and a maximum current of 10 mA/cm^2 , so as to form a surface coating of titanium phosphate. It is then rinsed in de-ionised water again. The surface, which is initially pale grey, turns to a darker matt grey as a consequence of the anodising, with a slightly yellow hue.

The implant is then immersed in a stirred 0.1 M aqueous solution of silver nitrate, and left for 2 hours.

As a result of ion exchange there is consequently some silver phosphate in the titanium phosphate coating. The implant is then ready to be implanted. During exposure to body fluids there will be a slow leaching of silver ions from the phosphate layer, so that any bacteria in the immediate vicinity of the implant are killed. Infection arising from the implant is therefore suppressed.

Experimental samples of this titanium alloy were cleaned, anodised to form a layer of titanium phosphate, and then subjected to ion exchange to form silver phosphate, following the procedure described above. One sample was placed in direct daylight for 110 hours; the exposed surface became darkened as a result of this exposure to daylight, indicating the formation of silver metal by photo-reduction. The other sample was immersed in a solvent containing a mixture of 4 M nitric acid and 0.5 M sodium fluoride (equivalent to hydrofluoric acid) to dissolve the coating. The dark grey surface coating was removed completely within 3 minutes, leaving a silver-grey finish. The resulting solution was analyzed for the presence of silver by atomic absorption spectrometry, and the concentration of silver was found to be equivalent to an average surface loading of 73

$\mu\text{g}/\text{cm}^2$.

Claims

1. A metal implant for use in a surgical procedure, the implant having a surface layer that is integral with the metal substrate, and which incorporates a biocidal material.
2. An implant as claimed in claim 1 wherein the integral surface layer is generated by growing the layer from the metal.
3. An implant as claimed in claim 2 wherein the surface layer is generated by an anodising process.
4. An implant as claimed in claim 3 wherein the surface layer comprises a metal phosphate.
5. An implant as claimed in any one of claims 2 to 4 wherein the biocidal material comprises metal ions absorbed within the surface layer.
6. An implant as claimed in claim 5 wherein the biocidal material comprises silver.
7. An implant as claimed in claim 1 wherein the integral surface layer is generated by first depositing the layer and then subjecting the layer and the implant to diffusion bonding so that the layer becomes integral with the metal of the implant.
8. An implant as claimed in any one of the preceding claims wherein the surface of the implant is highly polished before provision of the surface layer.

9. A metal implant for use in a surgical procedure substantially as hereinbefore described.

5 15651 MdH

P.T. Mansfield
Chartered Patent Agent
Agent for the Applicants

Abstract

Metal Implants

5 A metal implant for use in a surgical procedure is
provided with a surface layer that is integral with the
metal substrate, and which incorporates a biocidal
material. The surface layer may be grown from the metal
substrate, by anodising, and the biocidal material
10 incorporated in it by ion exchange. Alternatively the
layer may be deposited by electroplating, followed by
diffusion bonding so as to become integral with the metal
substrate. In either case, silver is a suitable biocidal
material; and both the release rate and the quantity of
15 biocidal material should be low to avoid toxic effects on
body cells. Electropolishing the surface before formation
of the surface layer is also beneficial, and this may be
achieved by electropolishing.

20

15651 MdH